3-[(dimethylamino)diazenyl]-4.5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-carboxamide | 1252925-29-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[(dimethylamino)diazenyl]-4.5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-carboxamide
• 英文别名: 3-[(Dimethylamino)diazenyl]-4,5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-carboxamide；3-(dimethylaminodiazenyl)-4,5,6,7-tetrahydro-1-benzoselenophene-2-carboxamide
• CAS: 1252925-29-3
• 化学式: C₁₁H₁₆N₄OSe
• 分子量: 299.234
• InChiKey: PGFSGRJPVDGAES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  sodium selenide 、 2-chlorocyclohex-1-enecarbonitrile 、 氯乙酸乙酯 、 二甲胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.91h， 生成 3-[(dimethylamino)diazenyl]-4.5,6,7-tetrahydrobenzo[1,2-b]selenophene-2-carboxamide
  参考文献：
  名称：

  [EN] ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS
  [FR] MÉDICAMENTS ANTICANCÉREUX ET UTILISATIONS LIÉES À DES MÉLANOMES MALINS ET À D'AUTRES CANCERS

  摘要：

  硒吡喃三氮烯类似物，它们的组成物，互变异构体，立体异构体，多晶形态，水合物，溶剂合物，以及药学上可接受的盐和它们的混合物可用于治疗转移性恶性黑色素瘤和其他癌症。硒吡喃三氮烯类似物具有一般式(I)或(II)：其中取代基R1、R2、R3、R6和R7如规范中所述。其他可用这些化合物治疗的癌症包括但不限于恶性黑色素瘤、白血病、淋巴瘤（霍奇金病和非霍奇金病）、肉瘤（尤因肉瘤）、脑肿瘤、中枢神经系统（CNS）转移瘤、胶质瘤、癌症如乳腺癌、前列腺癌、肺癌（小细胞和非小细胞）、结肠癌、胰腺癌、头颈癌和口咽鳞状细胞癌。

  公开号：

  WO2010125575A1

文献信息

• Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
  申请人：Kasina Laila Innova Pharmaceuticals Private Limited

  公开号：US08143237B2

  公开（公告）日：2012-03-27

  Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

  Selenopheno triazene类似物，它们的组成，互变异构体，立体异构体，多晶体，水合物，溶剂物和药学上可接受的盐以及它们的混合物，可用于治疗转移性恶性黑色素瘤和其他癌症。 Selenopheno triazene类似物具有一般式（I）或（II）：其中取代基R1，R2，R3，R6和R7如规范中所述。其他可能使用这些化合物治疗的癌症包括但不限于恶性黑色素瘤，白血病，淋巴瘤（霍奇金氏和非霍奇金氏），肉瘤（尤因肉瘤），脑肿瘤，中枢神经系统（CNS）转移，胶质瘤，如乳腺癌，前列腺癌，肺癌（小细胞和非小细胞），结肠癌，胰腺癌，头颈癌和咽喉鳞状细胞癌。
• ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS
  申请人：GOKARAJU Ganga Raju

  公开号：US20100272678A1

  公开（公告）日：2010-10-28

  Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R 1 , R 2 , R 3 , R 6 , and R 7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

  Selenopheno triazene类似物、它们的组合物、互变异构体、立体异构体、多晶形态、水合物、溶剂化物以及药学上可接受的盐和混合物可用于治疗转移性恶性黑色素瘤和其他癌症。Selenopheno triazene类似物的一般式为(I)或(II)，其中取代基R1、R2、R3、R6和R7如说明书中所述。这些化合物可用于治疗的其他癌症包括但不限于恶性黑色素瘤、白血病、淋巴瘤（霍奇金病和非霍奇金病）、肉瘤（尤因肉瘤）、脑瘤、中枢神经系统（CNS）转移、胶质瘤、癌症如乳腺癌、前列腺癌、肺癌（小细胞和非小细胞）、结肠癌、胰腺癌、头颈癌和咽喉鳞状细胞癌。
• [EN] ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS<br/>[FR] MÉDICAMENTS ANTICANCÉREUX ET UTILISATIONS LIÉES À DES MÉLANOMES MALINS ET À D'AUTRES CANCERS
  申请人：KASINA LAILA INNOVA PHARMACEUT

  公开号：WO2010125575A1

  公开（公告）日：2010-11-04

  Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

  硒吡喃三氮烯类似物，它们的组成物，互变异构体，立体异构体，多晶形态，水合物，溶剂合物，以及药学上可接受的盐和它们的混合物可用于治疗转移性恶性黑色素瘤和其他癌症。硒吡喃三氮烯类似物具有一般式(I)或(II)：其中取代基R1、R2、R3、R6和R7如规范中所述。其他可用这些化合物治疗的癌症包括但不限于恶性黑色素瘤、白血病、淋巴瘤（霍奇金病和非霍奇金病）、肉瘤（尤因肉瘤）、脑肿瘤、中枢神经系统（CNS）转移瘤、胶质瘤、癌症如乳腺癌、前列腺癌、肺癌（小细胞和非小细胞）、结肠癌、胰腺癌、头颈癌和口咽鳞状细胞癌。